Special Issue "Antivenom and Venom Therapeutics"
Deadline for manuscript submissions: closed (30 June 2014)
Antivenom is the only scientifically-validated treatment against snakebite and is formulated as either purifyed IgGs or as pepsin (F(ab/)2)/papain (Fab) cleaved fragments raised against venoms of single (monospecific) or multiple snake species (polyspecific). Although the treatment aims to neutralize the toxic components of snake venom, its formulation frequently fails to take into account their distinct variation in representation and immunogenicity. Consequently, the often low, clinically-relevant fraction needed to achieve reversal of envenoming frequently leads to the administration of life-threatening volumes that compromise the effectiveness of the treatment and further increase its cost and availability. This Special Issue of Toxins aims to provide a comprehensive look at the challenges of antivenom therapy and the current strategies for improving such therapy.
Dr. Bryan Fry
Dr. Camila Renjifo
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed Open Access monthly journal published by MDPI.
- snake venom